NEW YORK, NY / ACCESSWIRE / November 20, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
HMLP Shareholders Click Here: https://www.zlk.com/pslra-1/hoegh-lng-partners-lp-loss-submission-form?prid=21423&wire=1
CEI Shareholders Click Here: https://www.zlk.com/pslra-1/camber-energy-inc-loss-submission-form?prid=21423&wire=1
SBTX Shareholders Click Here: https://www.zlk.com/pslra-1/silverback-therapeutics-inc-loss-submission-form?prid=21423&wire=1
* ADDITIONAL INFORMATION BELOW *
Hoegh LNG Partners Lp (NYSE:HMLP)
HMLP Lawsuit on behalf of: investors who purchased August 22, 2019 - July 27, 2021
Lead Plaintiff Deadline : December 27, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/hoegh-lng-partners-lp-loss-submission-form?prid=21423&wire=1
According to the filed complaint, during the class period, Hoegh LNG Partners Lp made materially false and/or misleading statements and/or failed to disclose that: (1) the Partnership was facing issues with the PT Perusahaan Gas Negara ("PGN") Floating Storage Regasification Unit ("FSRU") Lampung charter; (2) as a result, the PGN FSRU Lampung charterer would state that it would commence arbitration to declare the charter null and void, and/or to terminate the charter, and/or seek damages; (3) the Partnership would need to find alternative refinancing for its PGN FSRU Lampung credit facility; (4) the PGN FSRU Lampung credit facility matured in September 2021, not October 2021 as previously stated; (5) the Partnership would be forced to accept less favorable refinancing terms with regards to the PGN FSRU Lampung credit facility; (6) Höegh LNG would not extend the revolving credit line to the Partnership past its maturation date; (7) Höegh LNG would reveal that it "will have very limited capacity to extend any additional advances to the Partnership beyond what is currently drawn under the facility"; (8) as a result of the foregoing, the Partnership would essentially end distributions to common units holders; (9) the COVID-19 pandemic was not the sole or root cause of the Partnership's issues in Indonesia, in 2019, before the pandemic, there were already a very low amount of demand in Indonesia for the Partnership's gas; (10) the auditing, tax, nor maintenance of PGN FSRU Lampung were not the sole or root cause(s) of the Partnership's issues in Indonesia; and (11) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Camber Energy, Inc. (NYSE:CEI)
CEI Lawsuit on behalf of: investors who purchased February 18, 2021 - October 4, 2021
Lead Plaintiff Deadline : December 28, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/camber-energy-inc-loss-submission-form?prid=21423&wire=1
According to the filed complaint, during the class period, Camber Energy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Camber overstated the financial and business prospects of Viking as well as the combined company post merger; (ii) Camber failed to apprise investors of, and/or downplayed, the fact that its acquisition of a controlling interest in Viking would exacerbate the Company's delinquent financial statements and listing obligations with the NYSE; (iii) an institutional investor was diluting Camber's shares at a significant rate following the Company's July 12, 2021 update regarding the number of its shares of common stock issued and outstanding; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Silverback Therapeutics, Inc. (NASDAQ:SBTX)
This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive.
Lead Plaintiff Deadline : January 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/silverback-therapeutics-inc-loss-submission-form?prid=21423&wire=1
According to the filed complaint, (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: